Access to the 340B program is essential for pharmacies and hospitals to continue to provide essential healthcare services in their communities. SB 94, introduced by Senator Sam Singh, prohibits a manufacturer or manufacturer's agent from doing any of the following:
- Deny, restrict, prohibit, condition, discriminate against, or otherwise limit the acquisition of a 340B drug by a 340B entity.
- Deny, restrict, prohibit, condition, discriminate against, or otherwise limit the acquisition of a 340B drug by, or the delivery of a 340B drug to, a pharmacy that is under contract with or otherwise authorized by a 340B entity to receive a 340B drug on behalf of the 340B entity.
The legislation was voted out of the Senate 33-3 on Thursday, March 6. The bill now advances to the House, where it has been referred to the House Health Policy Committee.
Please take the time to contact your state representative and encourage their support for SB 94 by highlighting the benefits this program has for your community.